Nektar Therapeutics
NKTR • NASDAQ
Nektar Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Howard W. Robin, with a market cap of $2.0B.
CEOHoward W. Robin
Next Earnings
Upcoming earnings announcement for Nektar Therapeutics
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.78
Revenue Estimate
$10.9M
Earnings History
Past 12 earnings reports for Nektar Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 12, 2026 | Q4 2025 | -$1.78Est: -$3.20 | +44.4% | $21.8MEst: $10.1M | +116.8% | — |
| Nov 6, 2025 | Q3 2025 | -$1.87Est: -$2.81 | +33.5% | $11.8MEst: $10.4M | +13.9% |  10-Q |
| Aug 7, 2025 | Q2 2025 | -$2.95Est: -$3.12 | +5.4% | $11.2MEst: $10.0M | +12.2% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.24Est: -$0.18 | -33.3% | $10.5MEst: $15.6M | -33.0% | 10-Q |
| Mar 12, 2025 | Q4 2024 | -$0.15Est: -$0.19 | +21.1% | $29.2MEst: $36.7M | -20.4% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.18Est: -$0.21 | +14.3% | $24.1MEst: $18.3M | +32.0% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.25Est: -$0.20 | -25.0% | $23.5MEst: $17.5M | +33.9% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.19Est: -$0.19 | 0.0% | $21.6MEst: $15.3M | +41.1% | 10-Q |
| Mar 4, 2024 | Q4 2023 | -$0.22Est: -$0.21 | -4.8% | $23.9MEst: $18.1M | +32.3% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.19Est: -$0.20 | +5.0% | $24.1MEst: $21.3M | +13.3% | — |
| Aug 8, 2023 | Q2 2023 | -$0.27Est: -$0.28 | +3.6% | $20.5MEst: $21.8M | -6.1% | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.25Est: -$0.25 | 0.0% | $21.6MEst: $19.8M | +8.8% | 10-Q |